Madrigal Pharmaceuticals Inc
MDGLHealthcare|Biotechnology|USA
$536.70
-23.77 (-4.24%)
Tangible Book
$23.27
Upcoming Data Readouts (5)
Dec 2026
Est. completion
P3NASH
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222n=845
Mar 2027
Est. completion
P3Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219n=810
Jan 2028
Est. completion
P3NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429n=1,759
Aug 2028
Est. completion
P2MASH - Metabolic Dysfunction-Associated Steatohepatitis
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601n=120
Apr 2030
Est. completion
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra Pregnancy and Lactation Registry
NCT07541469n=10